Puma Biotechnology Inc (NAS:PBYI)
$ 4.65 -0.29 (-5.87%) Market Cap: 224.31 Mil Enterprise Value: 241.87 Mil PE Ratio: 14.53 PB Ratio: 4.39 GF Score: 59/100

Puma Biotechnology Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 08:00PM GMT
Release Date Price: $8.36 (+0.24%)
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. We're going to get started. Up next, we have Puma Biotechnology.

With that, Chairman and CEO Alan Auerbach, take it from here.

Alan H. Auerbach
Puma Biotechnology, Inc. - Founder, Chairman, President, CEO & Secretary

Great. Thank you. Just a reminder that I'll be making forward-looking statements.

So on this slide, you can see Puma's product pipeline. It consists of the drug neratinib, which we have tested across a number of different indications and is also on the market as well. As you can see, the drug is marketed in the U.S., Europe and a number of other countries in extended adjuvant HER2-positive breast cancer. We also have it in testing in metastatic breast cancer, in metastatic breast cancer with brain mets and then in a certain subset of breast cancer patients that have a genetic mutation in HER2.

So first, talk about the commercial aspects of our business. We currently sell neratinib, which is a brand name

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot